AUTL — Autolus Therapeutics Share News
0.000.00%
Last trade - 00:00- $428.49m
- $476.32m
- $75.39m
Autolus Therapeutics PLC expected to post a loss of 48 cents a share - Earnings Preview
Autolus Therapeutics rises on FDA tag for cancer therapy
Brief: FDA Grants Regenerative Medicine Advanced Therapy Designation To Autolus’ Car T Cell Therapy
Brief: Autolus Therapeutics Files Prospectus Related To Resale By Selling Securityholders Of Up 21.3 Mln Adss
Brief: Autolus Therapeutics Receives EMA Orphan Medical Product Designation For Obe-Cel For Treatment Of Acute Lymphoblastic Leukemia
Autolus Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
Autolus Therapeutics PLC expected to post a loss of 46 cents a share - Earnings Preview
Brief: Autolus Therapeutics Announces Publication Describing Novel Cell Programming Technology
Brief: Autolus Therapeutics Announces Retirement Of Chief Financial Officer And Succession Plan
Brief: Autolus Therapeutics Presents Positive Obe-Cel Data
Brief: Autolus Therapeutics Announces The Appointment Of Dr. William D. Young As A Non-Executive Director
Autolus Therapeutics jumps on $250 mln investment by Blackstone unit
Brief: Autolus Therapeutics Says Blackstone Life Sciences To Invest Up To $250 Million In Co
Press Digest: Wall Street Journal - Nov 8
Media: Blackstone to invest up to $250 million in Autolus Therapeutics of U.K.- Wall Street Journal
Autolus Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Autolus Therapeutics Reports Third Quarter 2021 Financial Results And Operational Progress
Syncona Limited - Autolus reports Q3 2021 Financial Results
Autolus Therapeutics PLC expected to post a loss of 51 cents a share - Earnings Preview